Faculty

David T. Rubin, MD, FACG, AGAF, FACP, FASGE (Moderator) Joseph B. Kirsner Professor of Medicine Section Chief, Gastroenterology, Hepatology and Nutrition Co-Director, Digestive Diseases Center University of Chicago Medicine Chicago, IL

Millie D. Long, MD, MPH Associate Professor of Medicine, Division of Gastroenterology and Hepatology Director, Gastroenterology and Hepatology Fellowship Program University of North Carolina at Chapel Hill Chapel Hill, NC

Statement of Need

Clinicians caring for patients with ulcerative colitis must be aware of how the management of UC is evolving. With the increasing number of treatment choices for patients with UC, real-world effectiveness and clinical trials data may facilitate the identification of the right treatment for the right patient. Additionally, the UC management paradigm has shifted from clinical remission mainly based on symptoms to objective parameters such as endoscopic healing.

This CME Outfitters interactive symposium will feature expert faculty presenting real-world cases that illustrate challenges, knowledge and practice gaps, application of principles to practice and how best to incorporate into practice.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Evaluate comparative effectiveness data from real-world experience and clinical trials of advanced UC treatments.
• Apply recent UC guidelines and evidence for advanced therapies to select the right treatment for the right patient.
• Select robust objective treatment targets for patients with UC, with the goal of achieving deep remission and mucosal healing.

The following learning objectives pertain only to those requesting CNE or CPE credit:

• Evaluate comparative effectiveness data from real-world experience and clinical trials of advanced UC treatments.
• Identify recent UC guidelines and evidence for advanced therapies to select the right treatment for the right patient.
• Describe robust objective treatment targets for patients with UC, with the goal of achieving deep remission and mucosal healing.

Financial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

Gastroenterologists, primary care physicians, nurse practitioners, physician assistants, nurses, and pharmacists.

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15) CEUs). Universal Activity Number:
Live: 0376-0000-19-028-L01-P

Type: knowledge-based

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Format: 
Live activity

Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit^TM from organizations accredited by the Accreditation Council for Continuing Medical Education.

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Rubin reports that he receives grants from AbbVie Inc.; Genentech, Inc./Roche; Janssen Pharmaceuticals, Inc.; Prometheus Laboratories Inc.; Shire; and Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for AbbVie Inc.; AbGenomics; Allergan; Arena Pharmaceuticals, Inc.; Biomica; Bristol-Myers Squibb Company; Dizal Pharmaceutical; Eli Lilly and Company; Ferring Pharmaceuticals Inc.; Genentech, Inc./Roche; Janssen Pharmaceuticals, Inc.; Medtronic; Merck & Co., Inc.; Napo Pharmaceuticals, Inc.; Pfizer Inc.; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and TARGET PharmaSolutions, Inc. He is on the Board of Trustees for the American College of Gastroenterology; Co-Founder, CFO of Cornerstones Health, Inc. (non-profit); and Co-Founder of GoDuRn, LLC. 

Dr. Long reports that she receives grants and research support from Pfizer Inc. and Takeda Pharmaceuticals U.S.A., Inc. She is on the speakers bureau for AbbVie Inc. and UCB, Inc. She is a consultant for AbbVie Inc.; Janssen Pharmaceuticals; Takeda Pharmaceuticals U.S.A., Inc.; TARGET PharmaSolutions, Inc.; UCB, Inc.; and Valiant Pharmaceuticals.

Tony Graham, MD (peer reviewer) has no disclosures to report.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty has been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS(877.263.7767).

MM-094LS-102619-20